Link Technologies Ltd., an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has launched two modified phosphoramidite ranges to complement its existing extensive portfolio of products to support oligonucleotide synthesis. For triplex, antisense and gene targeting studies, the RNA-type phosphoramidites provide nuclease resistance and stability, while the new ethyl phosphoramidites improve oligonucleotide stability and delivery into cells, making them ideal for therapeutic applications.
Building on from the existing range of standard nucleobase RNA phosphoramidites and CPG supports, the modified RNA-type phosphoramidites comprise two 2’-OMe RNA products, 2’-OMe-I and 2’-OMe-T. Oligonucleotides containing these modifications are ideal for triplex, antisense and gene targeting studies, as they form more stable hybrids with complementary RNA strands compared to equivalent DNA or RNA strands. Furthermore, when used in gene targeting studies, the addition of 2’-OMe residues into triplex forming oligonucleotides (TFO’s), confers the same nuclease resistance and stability as seen with duplexes.
Oligonucleotides synthesised from Link’s new ethyl phosphoramidites (available with standard nucleobase protection) have a neutral charge and slightly lipophilic character, which improves their delivery into the cell. Perfect for use in therapeutic applications, oligonucleotides containing these ethyl groups are nuclease resistant and have been shown to inhibit protein expression and cell growth when taken up by liposomes.
The new modified phosphoramidites provide increased nuclease resistance and stability, extending the experimental capabilities available.